Zydus' Oxcarbazepine Tablets Receive Final Approval from USFDA
Zydus Lifesciences Limited declared on Tuesday that it had received final approval from the United States Food and Drug Administration (USFDA) for Oxcarbazepine Tablets USP in 150 mg, 300 mg, and 600 mg strengths. These tablets, equivalent to the US Reference Listed Drug (RLD) Trileptal Tablets, are used to treat seizure disorders, including epilepsy. Zydus will manufacture the drugs at its formulation manufacturing facility in Baddi, Himachal Pradesh, India.
IJCP Editorial Team
Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.
More FAQs by IJCP Editorial Team
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks
Please login to comment on this article